Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health 15 September
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions 11 September
